Business
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunitiesCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. “We’re thrilled to welcome Dallan to Vor Bio at this important inflection point,” said Jean-Paul Kres
About this update from Vor Biopharma Inc.
[{"type":"image","alt":"Vor Biopharma","displaySize":"","headline":null,"caption":"Vor Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B2LYyFLcnDdgjzJKo4HDhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108}},"lazy":false},{"type":"text","content":"Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities","length":133,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately.","length":265,"tagName":"p"},{"type":"text","content":"“We’re thrilled to welcome Dallan to Vor Bio at this important inflection point,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. “His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy.”","length":396,"tagName":"p"},{"type":"text","content":"Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy. Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at...